A new UK trial will screen thousands of high-risk adults for early liver disease in primary care, aiming to improve diagnosis ...

Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the ...

Blood-based biomarkers and imaging measures may help monitor MASH disease activity, potentially reducing reliance on liver biopsies. Semaglutide treatment showed significant improvements in liver ...

The often dreaded colonoscopy could become less common as the accuracy of non-invasive detection tools improves, giving people more options for screening, according to a recent study in the ...